Cu-CANF-Comb

Phase 1Small molecule

WWashington University School of Medicine

Cu-CANF-Comb is one of 32 small molecule programs targeting Atherosclerosis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AtherosclerosisActive, not recruiting

AtherosclerosisPhase 1

Active, not recruiting

Competition

Competitive Landscape

165 competitors in Atherosclerosis

#DrugCompanyPhaseTrials

Avandia

Alnylam Pharmaceuticals

Phase 3

3 2

Estrace

Novo Nordisk

Phase 3

2 3

Depo-Provera

Pfizer

Phase 3

2 4

Colcrys

Alnylam Pharmaceuticals

Phase 3

1 5

Glucotrol

Pfizer

Phase 3

1 6

Brilinta

AstraZeneca

Phase 3

1 7

Ilaris

Novartis

Phase 3

—8

Benicar

CCosette Pharmaceuticals, Inc.

Phase 3

2 9

Altoprev

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

2 10

Colestid

Pfizer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Atherosclerosis1 trial

PET Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis (Volunteer - BioD and Safety Study)

Completed·WWashington University School of Medicine·Phase 1·NCT02498379·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cu-CANF-Comb. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cu-CANF-Comb compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cu-CANF-Comb. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Washington University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: WWashington University School of Medicine

Cu-CANF-Comb

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Atherosclerosis1 trial

References

Drug Info

Quick Facts

Related News